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Parkinson’s disease (PD) is a neurodegenerative disease of the central nervous system
characterized by motor impairment. The pathological hallmark and cause is the
degeneration and death of the dopaminergic neurons in the structure of the brain known as
substantia nigra pars compacta. Glial cell line-derived neurotrophic factor (GDNF), being a
potent survival-promoting agent for dopaminergic neurons, has long been researched as a
therapeutical agent in the treatment of PD. So far, the success has been limited. Many of
the obstacles associated with GDNF could be overcome by GDNF mimics, small
molecules functionally similar to GDNF but with better pharmacological properties. The
purpose of this graduate study was to characterize four potential small-molecule GDNF
mimics developed in research group led by Academy Professor Mart Saarma at the
Institute of Biotechnology, University of Helsinki.
GDNF’s neurotrophicity is attributed to the activation of intracellular signalling pathways
such as the MAPK (mitogen-activated protein kinase) and the PI3K (the phosphoinositide
3-kinase) pathway. GDNF activates these pathways through the GDNF receptor complex
consisting of a transmembrane receptor tyrosine kinase RET and a co-receptor known as
GDNF family receptor ?1 (GFR?1). Weather the potential GDNF mimics activate the same
intracellular signalling pathways through the GDNF receptor complex and weather or not
the molecules have survival promoting effects on dopaminergic neurons were the key
questions this graduate study addresses. The methods used include a luciferase reporter
gene-based system in cells expressing the GDNF receptor complex (developed by
Sidorova et al.) for monitoring MAPK activation, phosphorylation assays based on western
blot to study activation of the aforementioned cellular components associated with GDNF
and finally, a survival assay utilizing primary dopaminergic neurons to study survival
promoting effects of the potential GDNF mimics.
Of the four potential GDNF mimics one was conclusively shown to possess functional
qualities similar to those of GDNF. As for the other three, data acquired were promising yet
insufficient to make such claims and further experiments are required.
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Parkinsonin tauti on keskushermoston rappeumasairaus, joka aiheuttaa pääasiassa
motorisia oireita. Taudin suurin yksittäinen aiheuttaja on mustatumakkeen dopamiinia
tuottavien hermosolujen rappeutuminen. GDNF (glial cell line-derived neurotrophic factor)
on neurotrofinen tekijä, joka estää näiden dopaminergisten solujen kuolemaa ja jota on
pitkään tutkittu sovellettavaksi Parkinsonin taudin hoidossa. GDNF soveltuu kuitenkin
huonosti lääkeaineeksi, ja parempia tuloksia voitaisiin saavuttaa toiminnallisesti GDNF:n
kaltaisilla pienimolekyylisillä yhdisteillä. Tämän opinnäytetyön tavoitteena oli karakterisoida
neljä tällaista yhdistettä, jotka on kehitetty akatemiaprofessori Mart Saarman johtamassa
tutkimusryhmässä Biotekniikan instituutissa, Helsingin yliopiston erillislaitoksessa.
GDNF:n neurotrofisuus perustuu solunsisäisen signalointireittien, kuten MAPK:n
(mitogeenien aktoivoima proteiinikinaasi) ja PI3K:n (fosfoinositidi-3-kinaasi) aktivoimiseen.
GDNF aktivoi nämä GDNF-reseptorikompleksin välityksellä, joka koostuu solukalvon
läpäisevästä RET-tyrosiinikinaasireseptorista ja solukalvoon ankkuroidusta GFR?1-
apureseptorista (GDNF family receptor ?1). Tässä opinnäytetyössä sanalla karakterisointi
tarkoitetaan sen selvittämistä, kykenevätkö tutkittavat yhdisteet aktivoimaan samoja
solunsisäisiä signalointireittejä kuin GDNF GDNF-reseptorikompleksin kautta ja mikä
tärkeintä, onko näillä yhdistellä dopaminergisten hermosolujen kuolemaa estävä vaikutus.
Tärkeimmät tekniikat olivat lusiferaasireportterigeenianalyysi MAPK-signalointireitin ja
western blot -analyysi sekä tämän että PI3K:n ja GDNF-reseptorikompleksin
komponenttien aktivaation määrittämiseksi. Lopuksi määritettiin hermosolujen kuolemaa
estävä vaikutus primäärisillä dopaminergisillä neuroneilla in vitro.
Neljästä pienimolekyylisestä yhdisteestä yhden voitiin osoittaa toimivan GDNF:n tavoin
tutkittujen ominaisuuksien osalta. Kolmen muun yhdisteen kohdalla tutkimus on kesken ja
GDNF:n kaltaisuus on toistaiseksi osoittamatta.
Avainsanat GDNF, Parkinsonin tauti
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Abbreviatons
AKT A protein kinase in the PI3K pathway
ARTN Artemin, a GFL
BSA Bovine serum albumin
BT1x BT13, BT16, BT17 and BT18, the potential small-molecule
GDNF mimics under investigation
DA Dopamine, dopaminergic
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
ERK1/2 Extracellular signal-regulated kinase 1 (p44 MAPK) and 2
(p42 MAPK) in the MAPK pathway
FBS Fetal bovine serum
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GDNF Glial cell line-derived neurotrophic factor, a GFL
GFL GDNF family ligand, see ARTN, GDNF, NRTN and PSPN
GFP Green fluorescent protein
GFR?1-4 GDNF family receptor ? 1, 2, 3 or 4
HBSS Hank’s Balanced Salt Solution
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid, a buffer
MAPK Mitogen-activated protein kinase (such as ERK1/p44 MAPK
and ERK2/p42 MAPK) and the name of the intracellular
signalling pathway
MW Molecular weight
NRTN Neurturin, a GFL
PBS Phosphate buffered saline
PD Parkinson’s disease
PFA Paraformaldehyde
PI3K Phosphoinositide 3-kinase and the name of the intracellular
signalling pathway
PSPN Persephin, a GFL
RET A receptor tyrosine kinase, from REarranged during
Transfection
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TBS Tris-buffered saline
TBST A buffer containing 50 mM Tris-HCl (pH 7,4) 150 mM NaCl
and 0,15 % Tween 20
TBSTX A buffer containing 50 mM Tris-HCl (pH 7,4) 150 mM NaCl
and 0,4 % Triton X-100
TH Tyrosine hydroxylase, a marker for dopaminergic neurons
UPDRS Unified Parkinson’s Disease Rating Scale
WB Western blot
11 Introduction
Several diseases such as Parkinson’s, Alzheimer’s and Huntington’s occur as a result of
progressive neurodegenerative processes in which neurons lose structure, function and
as a result, die. The mechanisms underlying neurodegeneration are not well
understood and existing therapies offer only symptomatic relief – known treatments do
not reverse, stop or even slow down neuronal degeneration. Neurotrophic factors, a
class of proteins crucial for the development and maintenance of neurons, promise to
change this. Efforts are being made to harness the protective and restorative
properties of neurotrophic factors in an attempt to battle neurodegeneration. One of
the  teams working in  this  field  is  the  research group led  by  Academy Professor  Mart
Saarma in the Institute of Biotechnology at the University of Helsinki. This graduate
study is based on experiments conducted as a member of this group during the year
2011 under the supervision of Dr. Yulia Sidorova.
One of the most promising candidates for the treatment of Parkinson’s disease is the
glial-cell-line-derived neurotrophic factor (GDNF). GDNF has been shown to promote
survival and sprouting of dopaminergic neurons – the neuronal subtype that
degenerates and dies in Parkinson’s disease – both in vitro and in vivo. However, GDNF
is far from an ideal pharmacological agent. Firstly, GDNF or cells producing GDNF must
be  delivered  straight  into  a  patient’s  brain  through  a  surgical  procedure.  More
importantly, the protein migrates poorly from the area of injection or production and
does not necessarily reach its target cells. These and a number of other problems stem
from  the  fact  that  GDNF  is  a  protein  and  could  very  well  be  solved  through  the
development of small molecules functionally similar to GDNF.
The purpose of this graduate study was the in vitro characterization of four synthetic
molecules developed by the group of Prof. Saarma in hopes of establishing functional
similarities between the four and GDNF. Utilizing cells expressing parts of, or the
complete, GDNF receptor complex, three approaches outlined in chapter 3 were used.
22 Review of the literature
This section covers the key concepts necessary for understanding the work about to be
presented and hopefully answers the questions why this research was conducted and
why it was conducted in a specific way. In essence, the section describes the human
movement and why it is compromised in Parkinson’s disease, how GDNF and other
neurotrophic factors factor in and why there is a need for small-molecule mimics.
2.1 The basal ganglia
Human movement is controlled by neural circuits that can be viewed as four distinct,
interconnected subsystems. The first consists of the lower motor neurons and the local
circuit neurons in the spinal cord and the brainstem. The local circuit neurons
contribute to motor activity by controlling the lower motor neurons that, in turn,
connect directly to musculature. Both the local circuit neurons and the lower motor
neurons (although more rarely) are controlled by upper motor neurons that comprise
the second subsystem. These neurons are found in the brainstem and the cerebral
cortex and are essential for initiating voluntary movements. The upper motor neurons
are further regulated by the third and fourth subsystems that are the cerebellum and
basal ganglia. [1.]
The  basal  ganglia  refer  to  a  group  of  nuclei  lying  deep  within  the  brain.  The  nuclei
relevant for motor control include the corpus striatum and the globus pallidus at the
base of the forebrain, the subthalamic nucleus in the ventral thalamus and the
substantia nigra at the base of the midbrain (Figure 1). The corpus striatum, consisting
of the caudate and the putamen, serves as an input to the basal ganglia. These
structures receive projections from different regions of the brain, especially from the
cerebral cortex. The way the inputs are organized in respect to the morphology of the
striatal neurons suggests that the corpus striatum acts to integrate incoming signals.
Further  convergence  is  evident  in  the  pallidum  (the  globus  pallidus  and  the  pars
reticulata subdivision of the substantia nigra), where the corpus striatum itself projects.
The pallidum is considered the output of the basal ganglia and connects eventually to
the upper motor neurons. There is functionally important internal circuitry governing
the output of the basal ganglia which is not described for the reason of relevance. [1.]
3Figure 1.   Left: Motor components of the human basal ganglia: the caudate and the putamen
(the corpus striatum), the globus pallidus and the substantia nigra pars reticulata (the
pallidum), the substantia nigra pars compacta and the subthalamic nucleus [1]. Right:
The main output of the basal ganglia is inhibitory. When excited, the corpus striatum
inhibits the tonically active inhibitory cells in the pallidum which allows other inputs to
excite  the  upper  motor  neurons.  In  a  way,  the  basal  ganglia  circuitry  acts  as  a  gate
that blocks unwanted movement. Huntington’s disease is a hyperkinetic movement
disorder in which striatal projections degenerate. The result is a reduction in the
inhibitory outflow of the basal ganglia. This allows the upper motor neurons to become
more easily activated and leads to the unwanted movement characteristic of
Huntington’s disease. In Parkinson’s disease however the cellular population most
severely affected are the dopaminergic neurons in the substantia nigra pars compacta.
Dopamine provided by the substantia nigra pars compacta modulates the excitability of
striatal neurons by cortical inputs. When nigral dopaminergic neurons degenerate, the
striatum becomes less responsive to excitatory inputs from the cortex. Unlike in
4Huntington’s disease, the parkinsonian brain is characterized by an increase in the in-
inhibitory outflow of the basal ganglia. Indeed, Parkinson’s disease and associated
movement disorders are hypokinetic. [1.]
2.2 Parkinson’s disease
Parkinson's disease (PD) is the second most common progressive degenerative
disorder of the central nervous system.  The disorder is age-related with 85 % of newly
diagnosed cases occurring in people over the age of 65 [2]. According to the Finnish
Parkinson Association PD is fairly common in Finland with the incidence of 1-2/1000 on
the population level and from over 70-year-olds as many as 2 % are affected. The
significance of Parkinson’s disease is increasing as is many parts of the world the
population is aging.
PD is characterized by the impairment of motor function. The set of motor symptoms
caused by the disease are collectively referred to as parkinsonism and include tremor
at rest, rigidity, postural instability and difficulty in initiating and executing voluntary
movement (akinesia, bradykinesia). Even though the most prominent signs of PD are
motor, significant nonmotor symptoms commonly develop. These include behavioral
and mental alterations (fatigue, depression, anxiety), cognitive deterioration to the point
of dementia, sleep disturbances and dysfunctions in the autonomic and sensory
nervous systems. PD is diagnosed chiefly on the basis of the clinical features and is
commonly evaluated using the Unified Parkinson’s Disease Rating Scale (UPDRS). [3.]
The vast majority of PD cases are idiopathic in etiology i.e. the cause is unknown.
Enviromental toxins have been suggested as a causative agent. Indeed, chemicals
such as 1,2,5,6-tetrahydropyridine (MPTP) and rotenone (a pesticide) have been linked
with the development of PD. The remaining 5-10 % of PD cases are estimated to be
caused by inheritable genetic mutations and often lead to an atypical clinical picture.
Study of genetics behind PD has shed some light to pathological mechanisms
underlying the disorder. These include disruptions in the proteolytic ubiquitin-
proteasome system, oxidative stress and mitochondrial dysfunction. Buildup of toxic
proteins has gained attention due to the fact that most PD patients develop
intracytoplasmic eosinophilic inclusions called Lewy bodies the main component of
which is ?-synuclein. In fact, a mutation in the gene encoding ?-synuclein was the first
to be linked to parkinsonism. More research is needed to determine what causes the
5majority of PD cases, whether it is the genetic or environmental factors, what they are
and how they work together to induce pathogenesis. [2.]
Most prominent but by means not the only pathological feature of PD is the
degeneration and death of dopaminergic (DA) neurons in the substantia nigra pars
compacta found at the base of the midbrain. The resulting disruption of the nigrostriatal
pathway and the subsequent deficiency of striatal DA are accountable for most of the
motor symptoms. These symptoms manifest when the putaminal dopamine content
has decreased 80 % (corresponds to 60 % loss of nigral DA neurons). Until the onset
of symptoms dopamine deficiency is compensated by supersensitization of DA
receptors. In addition to neuronal loss there is an increase in the number of nigral glial
cells and loss of neuromelanin that gives substantia nigra its dark color. [3.]
As the cause underlying degeneration and death of dopaminergic neurons in PD is
unknown, current treatments focus on symptomatic alleviation. This is achieved mainly
through the use of levodopa, a dopamine precursor that is converted into dopamine in
the central nervous system. Levodopa has revolutionized PD treatment but eventually
causes severe side effects such as response fluctuations and dyskinesias (drug-
induced involuntary movements). Other alternatives include DA agonists, dopamine
releasers and surgical procedures such as lesioning and deep brain stimulation [3].
The efficacy of the latter two is based on successfully blocking the abnormal,
pathological activity in affected neural circuits. [4]. Attempts to implant dopamine-
producing cells or to regenerate the remaining dopaminergic neurons using
neurotrophic factors offer to revolutionize the treatment of PD but are at least for now
far away from clinical practice.
2.3 Neurotrophic factors
Neuronal survival, growth and differentiation are dependent on trophic support. Neu-
rons receive this from the targets they innervate in the form of signaling molecules
known as neurotrophic factors. [1.] These small secretory proteins are currently
classified into four families: the neurotrophins, the neurokines (neurotrophic
cytokines), the glial-cell-line-derived neurotrophic factor (GDNF) family ligands (GFLs)
and the recently discovered family comprising cerebral dopamine neurotrophic factor
(CDNF) and mesencephalic-astrocyte-derived neurotrophic factor (MANF). [5.]
6The GDNF family of ligands consists of four members: GDNF, neurturin (NRTN), arte-
min (ARTN) and persephin (PSPN). All four GFLs have survival promoting effects on
several types of neurons including dopaminergic neurons. Other clinically important
neuronal populations supported by one or more GFLs include motor and sensory
neurons that are affected in motor neuron diseases and neuropathic pain, respectively.
Knockout studies have shown GFLs are important also in the developing nervous
system. Mice lacking GDNF, NRTN or their receptors show defects in the enteric and
parasympathetic innervation. ARTN seems to be required for the development of
sympathetic neurons. GDNF also has functions outside the nervous system in kidney
development and spermatogenesis. [6.]
Neurotrophic effects of GFLs are mediated by a multicomponent cell surface receptor
complex consisting of a signal-transducing and a ligand-binding unit. The signaling unit
is a transmembrane receptor tyrosine kinase known as RET (from REarranged during
Transfection). RET cannot bind a GFL directly. For this it needs a co-receptor (i.e. the
ligand-binding unit) which is one of the four GDNF family receptor ? proteins (GFR?1-
4). GDNF has the highest affinity to GFR?1, NRTN to GFR?2, ARTN to GFR?3 and
PSPN to GFR?4 (Figure 2). There is significant crosstalk, however. [6.] GDNF can bind
to GFR?2 and GFR?3 and all GFLs are able to bind to GFR?1 [7].
Figure 2.   Components of the GFL receptor complex: the signal-transducing, transmembrane
receptor tyrosine kinase RET shared by all GFLs and the ligand-binding co-receptors
GFRa1-4 preferred by GDNF, NRTN, ARTN and PSPN, respectively. Crosstalk not
shown.
As GFLs are homodimers, an active receptor complex consists of two units of RET
associated with two units of GFR? receptors that bind one GFL molecule. It is unclear
7whether a GFL is what allows the complex to assemble or if it merely stabilizes a pre-
preformed GFR?-RET complex [8]. In either case, a functional GFL-GFR?-RET
complex leads to transphosphorylation in the intracellular tyrosine kinase domains of
the two RET units. Resulting conformational changes promote activation of several
intracellular signaling cascades. [6.]
Neurotrophic properties of GDNF have been attributed to its activation of the
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK)
pathways [9] through the GDNF receptor complex (Figure 3). The PI3K cascade has
been shown to promote cell survival in midbrain dopaminergic neurons, an effect that
could be abolished by blocking this pathway [10]. Sustained and transient activation of
the MAPK pathway have been linked to neuronal differentiation and proliferation,
respectively [11].
Figure 3.   A simplified representation of two intracellular signaling pathways, MAPK and PI3K,
activated by a functional GDNF receptor complex.
82.4 Neurotrophic factors - a cure for Parkinson’s disease?
GDNF and other GFLs are known for their ability to support dopaminergic neurons.
ARTN and PSPN have demonstrated neuroprotective effects in animal models of
Parkinson’s disease [12, 13]. GDNF has shown not only neuroprotective but also
neurorestorative effects in several studies [14] as has NRTN [15, 16]. The onset of
symptoms in Parkinson’s disease can be attributed to the decreased dopamine content
in the striatum. Interestingly from a therapeutic standpoint, initial striatal dopamine
depletion is greater than suggested by the number of viable dopaminergic neurons left
[17, 18]. This could indicate there is a loss of dopaminergic phenotype prior to cell
death, something that could possibly be augmented using neurotrophic factors.
GDNF and NRTN have been subjected to clinical trial. Two small, open-label studies in
which GDNF was infused directly into the putamen of PD patients showed promising
results [19, 20, 21, 22]. More recently however, a randomized, double-blind phase II
clinical trial failed to demonstrate a significant improvement in GDNF-treated patients
compared to the placebo group [23]. However, the study has received a fair amount of
criticism regarding the delivery strategy and the age of the patient population [24].
Moreover, whether the study had sufficient statistical power to detect the benefits of
GDNF has been questioned [25, 26]. NRTN failed to show significant benefit in a
clinical trial evaluated using the UPDRS motor score [27]. However, a benefit was seen
15 and 18 months post treatment while the endpoint in the study was 12 months.
Based on what was learned, another study is on its way with a higher dosage, different
delivery strategy and more statistical power to demonstrate efficacy.
The therapeutic potential of GDNF in treatment of PD is undermined by several issues,
most importantly bioavailability. GDNF is unable to cross the blood-brain barrier and
requires surgery for it to be delivered successfully into a patient’s brain. Moreover,
affinity to heparan sulfate proteoglycans in the extra-cellular matrix restricts diffusion of
GDNF from the site of administration or secretion making it unable to reach the target,
i.e. the dopaminergic neurons in substantia nigra pars compacta. Aside from
bioavailability, there are several other issues to consider most of which arise from the
fact that GDNF is produced as a recombinant protein in bacteria followed by
modifications that render the protein biologically active. Not only is the practice
expensive compared to manufacture of traditional pharmaceuticals, the properties of
the product can also vary between batches. As for side-effects, recombinant GDNF has
9the potential to induce inflammation and the formation of anti-GDNF antibodies. More-
Moreover, RET is not the only receptor GDNF is able to signal through. GDNF can also
activate the neural cell adhesion molecule and syndecan glycoproteins. [8.]
2.5 GDNF mimetics as an alternative to GDNF
An alternative to GDNF therapy is being pursued. Research group led by Academy
Professor Mart Saarma is striving to develop small-molecule GDNF mimics, i.e.
molecules functionally similar to GDNF. These low molecular weight GDNF receptor
complex agonists would be able to cross the blood-brain barrier thus eliminating the
need for surgery that is needed for successful GDNF delivery. Moreover, these
molecules could be produced at a lower cost, with less variation between batches and
with better pharmacological properties (in addition to molecular size and permeability)
compared to GDNF. Finally, a GDNF mimic could be more specific than GDNF itself,
targeting only RET through GFR?1. [8.]
The fact that GDNF is a dimer and signals through a multi-component receptor
complex poses a question whether a small monovalent molecule can act similarly.
Many receptor tyrosine kinases are thought to be activated when an extracellular
bivalent ligand brings two receptor monomers together allowing the effective
phosphorylation of the intracellular tyrosine kinase domains. It is also possible that the
ligand merely induces a phosphorylation-promoting conformational change or
stabilization in an inactive or partially active receptor dimer (or in the case of the GDNF
receptor complex, a (GFR?)2(RET)2 tetramer). Small molecules could act similarly by
engaging so-called “hot spots” in preformed receptor complexes. [8.] This certainly
seems plausible as a study showed that a GFR?1-binding monovalent small molecule
can activate the GDNF receptor complex [28].
As discussed previously GDNF exerts its neurotrophic effects via the GDNF receptor
complex by activating several intracellular signalling pathways, particularly the
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK)
pathways.  In  order  to  find  small-molecule  alternatives  to  GDNF,  thousands  of
chemicals were subjected to high-throughput screening using cell lines expressing
components of the GDNF receptor complex and a luciferase-reporter-gene-based
system for monitoring MAPK activation. Several molecules able to activate luciferase
expression were identified. Based on the structures of these molecules a library of
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similar compounds was designed in silico. This focused library was subsequently syn-
synthesized and tested using the same reporter-gene-based method. Finally, four
molecules (named BT13, BT16, BT17 and BT18) belonging to the focused library were
found to activate luciferase expression. This graduate study focuses on the
characterization of these four compounds to study potential functional similarities they
share with GDNF.
3 Materials and methods
This chapter describes the methods used to achieve the aim of this graduate study, the
characterization of four potential small-molecule GDNF mimics (BT13, BT16, BT17 and
BT18). For clarity the methods (Table 1) were given short titles and are hereafter
referred to as the luciferase assay (I), phosphorylation assay (II-a and II-b) and survival
assay (III).
Table 1. An outline of methods used and the research questions they address.
First, the reporter cells used to discover the four compounds were used to study dose-
dependence in the compound-induced, MAPK-activation-associated luciferase
expression. Also, the question was addressed whether GFR?1, the component of the
Method(s) Cells Research question Variables
I Luciferase
assay
Luciferase reporter
gene-based assay
Strat?LUC,
Nostrat?
Compound-induced MAPK activation GFR?1/no
GFR?1,
dose
IIa Phosphorylation
assay: ERK1/2
and AKT
Western blot MG87RET +
GFR?1
Compound-induced activation of
ERK1/2 (MAPK pathway) and AKT
(PI3K pathway)
Time, dose
IIb Phosphorylation
assay: RET
Immunoprecipitation,
western blot
MG87RET +
GFR?1
Compound-induced activation of RET GFR?1/no
GFR?1
III Survival assay Immunohistochemistry,
computer-aided
quantification
Primary
dopaminergic
neurons
Survial-prmoting effects of
compounds
-
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GDNF receptor complex, is required for the compounds’ biological effect on reporter
cell lines (I).  Then, the compounds’ ability to promote activation of the GDNF receptor
complex  and  its  downstream  targets  MAPK  and  PI3K  was  studied  using  direct
phosphorylation assays. Activation of MAPK and PI3K pathways was investigated using
antibodies  specific  to  phosphorylated,  i.e.  active,  forms  of  ERK1/2  and  AKT  –
components of the MAPK and PI3K signalling cascades, respectively (IIa). Activation of
the GDNF receptor complex was examined by immunoprecipitating its component RET
and using immunoblot to determine the degree of phosphorylation (i.e. activation). In
addition,  requirement  of  the  GFR?1  for  compound-induced  RET  activation  was
investigated (IIb). Finally, the ability of the compounds to promote survival of primary
embryonic midbrain dopaminergic neurons in vitro was tested using a computer-aided
method based on tyrosine hydroxylase specific antibodies (a well-established marker
for dopaminergic neurons) (III).
3.1 Materials and cell lines
Recombinant human GDNF was obtained from Amgen. Compounds BT13, BT16,
BT17 and BT18 were supplied by collaborators.
All established cell lines used were derivatives of an MG87RET cell line. These murine
fibroblasts stably express RET (long isoform) but not GFR?1. To increase the solubility
of the compounds, the media contained 1 % dimethyl sulfoxide (DMSO) in analyses
using established cell lines (luciferase and phosphorylation assays) or 0,1 % DMSO
with primary cells (survival assay).
3.2 Luciferase assay
Luciferase assay was developed by Sidorova et al. to study GFL signaling through the
GDNF receptor complex. The assay features two cell lines expressing the PathDetect
ELK1 trans-reporting system (Stratagene) for monitoring MAPK pathway activation. In
addition, the first cell line (Strat?LUC) expresses both components of the GDNF
receptor complex, human GFR?1 and long isoform of RET. The second cell line
(NOstrat?)?expresses only RET. Both cell lines respond to GDNF (NOstrat? only in the
presence of soluble GFR?1). NOstrat? cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10 % fetal bovine serum (FBS), 15 mM HEPES
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(pH 7,2), 500 µg/ml Geneticin (Invitrogen), 100 µg/ml Normocin (InvivoGen) and 2
µg/ml puromycin. Strat?LUC cells were cultured in NOstrat? medium supplemented
with 2 µg/ml blasticidin S.
PathDetect ELK1 trans-reporting system is based on two plasmids (Figure 4). The first
plasmid constitutively expresses a fusion protein that consists of the activation domain
of ELK1 transcription activator and the DNA binding domain (DBD) of another
transcription activator, GAL4. The second plasmid contains GAL4 binding sites that
control the expression of Photinus pyralis luciferase gene. Phosphorylation of ELK1
activation domain by ERK, component of the MAPK pathway, drives the interaction
between the GAL4 DBD and its binding sites in the reporter plasmid leading to
luciferase espression. Luciferase catalyzes a reaction that produces luminescence
intensity of which correlates with the degree of MAPK pathway activation.
Figure 4.  Principle of the luciferase assay. Phosphorylation of the fusion protein expressed by
plasmid 1 allows its DNA binding domain (DBD) to interact with GAL4 binding sites in
plasmid  2  leading  to  luciferase  expression.  Luciferase  catalyses  the  oxidation  of
luciferin – a reaction that produces light. Adapted from Sidorova et al. [7].
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The conditions in which compounds’ ability to activate luciferase expression was tested
vary  slightly.  To  test  BT13  and  BT16  cells  were  seeded  in  medium  containing  no
selective antibiotics as is recommended (DMEM containing 10 % FBS, 15 mM HEPES,
pH 7,2 and 1 % DMSO). With BT17 and BT18 cells were grown overnight in their
respective maintenance mediums (see above) which was replaced 1-2 h prior to
proceeding with the analysis.
When analysing compounds BT13 and BT16, Strat?LUC and Nostrat? cells were
seeded in 20 000 cells/well density on 96-well cell culture plates (Greiner Bio-One) in
DMEM containing 10 % FBS, 15 mM HEPES (pH 7,2) and 1 % DMSO. On the
following day medium was replaced with DMEM containing 15 mM HEPES, 1 % DMSO
(negative control) and compounds BT13, BT16 (1-50 µM) or GDNF (25 ng/ml, positive
control).
To analyse BT17 and BT18, cells were seeded in maintenance medium (containing
selective antibiotics) which was replaced on the following day with DMEM containing
10 % FBS, 15 mM HEPES (pH 7,2) and 1 % dimethyl sulfoxide (DMSO). Half of this
medium was replaced with DMEM containing 15 mM HEPES, 1 % DMSO (negative
control) and compounds BT17, BT18 (1-50 µM) or GDNF (50 ng/ml).
Cells were incubated overnight in a humidified 5 % CO2 athomsphere at +37 °C and
lysed with 20 µl/well Passive Lysis Buffer (Promega) on a shaker at RT for 15 min. 10
µl of lysate and 20 µl of Luciferase Assay Substrate (Promega) were mixed on Black
IsoPlates (PerkinElmer) on ice.  A 1450 MicroBeta luminescence counter (PerkinElmer)
was used to measure luminescence (RT). Results from the second run were used.
Data are presented as M ± m where M represents the average of at least three repeats
and m the standard deviation.
3.3 Phosphorylation assays
Phosporylation  assays  regarding  AKT,  ERK1/2  (of  the  PI3K  and  MAPK  pathways,
respectively) and RET were conducted using the MG87RET cell line maintained in
DMEM supplemented with 10 % FBS, 100 µg/ml Normocin and 2 µg/ml puromycin and
transfected with human GFR?1 prior to analyses.
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Assaying phosphorylation of a given protein can be accomplished using antibodies spe-
cific to the phosphorylated form of this protein. Thus, it  is important to preserve the
protein in a phosphorylated state. This was accomplished with a combination of ice and
phosphatase inhibitors (sodium fluoride or NaF, sodium orthovanadate or Na3VO4) to
slow down reactions and to block phosphatase activity, respectively.
The  proteins  were  then  resolved  and  visualized  using  western  blot.  To  be  able  to
determinate phosphorylation induced by compounds or even GDNF, the overall protein
content in the lysates must be similar. To monitor this, a protein known as
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was stained. The gene encoding
GAPDH is considered a housekeeping gene and is stably and constitutively expressed in
most tissues making is suitable for this application [29].
In order to investigate RET phosphorylation, it was necessary increase its
concentration through immunoprecipitation. Precipitation is achieved with the help of
Sepharose beads covalently coupled with protein G. Protein G binds immunoglobulins,
in this case anti-RET antibodies, and allows RET to precipitate along with the heavy,
insoluble Sepharose.
3.3.1 Phosphorylation assay: ERK1/2 and AKT
MG87RET cells were seeded 100 000-120 000 cells/well on 12-well cell culture plates
(Greiner Bio-One) in DMEM containing 10 % FBS and 100 µg/ml Normocin. Cells were
grown overnight and transfected with human GFR?1 (or green fluorescent protein,
GFP for transfection control) using Lipofectamine 2000 (Invitrogen). The Lipofectamine
reagent and DNA were diluted in Opti-MEM I Reduced Serum Media (Invitrogen) and
combined according to manufacturer’s instructions. Cells were incubated with DNA-
Lipofectamine mixture diluted 1:5 in DMEM containing 10 % FBS and 100 µg/ml
Normocin for 4-5 h. After this the transfection mixture was replaced with DMEM
containing 10 % FBS andn100 µg/ml Normocin (unless otherwise stated).
Expression of GFP was confirmed on the following day using fluorescent microscopy
(Figure 5). Cells were starved for 4-5 h in serum-free DMEM containing 15 mM HEPES
and 1 % DMSO (negative control) and treated with compounds (1-50 µM) or GDNF
(50-100 ng/ml, positive control) for 1-90 min (unless otherwise stated). Immediately
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after, the cells were placed on ice and washed with ice-cold PBS containing 1 mM NaF
and 1 mM Na3VO4. The cells were then suspended in 100 µl/well 2x Laemmli buffer,
boiled for 10 min and stored in -20 °C.
Figure 5.  Green fluorescent protein (GFP) was used as a transfection control and to estimate
transfection efficiency. Fluorescent MG87RET cells (darker) expressing GFP
superimposed over cells under visual light.
For western blot, samples were first boiled for 2 min and centrifuged (16 000 rcf, 2
min). Proteins were separated using 12 % SDS-PAGE (sodium dodecyl sulfate
polyacrylamide gel electrophoresis), transferred onto a nitrocellulose membrane,
blocked with 10 % non-fat milk in TBST (50 mM Tris-HCl, pH 7,4, 150 mM NaCl, 0,15
% Tween 20) for 15 min at RT and incubated overnight at +4 °C with rabbit antibodies
against phospho-AKT (Cell Signaling) or phospho-ERK1/2 (Cell Signaling, 4695)
diluted 1:1000 in TBST containing 5 % BSA (bovine serum albumin). Membranes were
washed with TBST and incubated for 45 min at RT with horseradish peroxidase or
HRP-conjugated anti-rabbit antibodies (Amersham) diluted 1:3000 in TBST containing
3 % milk. Membranes were washed three times for 15 min at RT with TBST and
proteins were visualized using Pierce ECL substrate (Thermo Scientific) or, if
necessary, with SuperSignal ELISA Femto substrate (Thermo scientific). Images were
taken using LAS-3000 imager (Fujifilm).
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To confirm equal loading, membranes were stripped in buffer containing 62,6 mM Tris-
HCl pH 6,7, 2 % SDS and 0,2 % 2-mercaptoethanol for 20 min at 60 °C, rinsed with
PBS (phosphate buffered saline) and washed 3 times for 10 min with TBST.
Membranes were blocked as previously described, incubated for 1 h at RT or overnight
at +4 °C with mouse antibodies against GAPDH (Millipore) diluted 1:2000 - 1:6000 in
TBST containing 3 % milk. Membranes were washed, incubated for 45 min at RT with
HRP-conjugated antibodies against mouse (Dako). Membranes were washed and
proteins visualized as described above.
3.3.2 Phosphorylation assay: RET
MG87RET cells were seeded 100 000-125 000 cells/well on 6-well cell culture plates
(Greiner Bio-One) in DMEM containing 10 % FBS and 100 µg/ml Normocin. Cells were
transfected on the following day with human GFR?1 or GFP using Lipofectamine 2000
(Invitrogen) as described earlier in chapter 3.3.1. Cells were starved for 4-5 h in serum-
free DMEM containing 15 mM HEPES and 1 % DMSO (negative control) before
stimulating with compounds BT13 and BT18 (5-50 µM) or GDNF (100 ng/ml, positive
control) for 15 min.
Cells were placed on ice, washed with ice-cold PBS containing 1 mM NaF and 1 mM
Na3VO4 and lysed for approximately 1 h on a shaker with 1 ml/well modified RIPA
(radioimmunoprecipitation assay) buffer (10 % glycerol, 1 % Triton X-100, 1 % NP-40,
0,25 % Na-deoxycholate, 1 mM NaF, 1 mM Na3VO4, 1 mM EDTA, Mini Protease
Inhibitor Coctail, Roche). Cell debris was precipitated by centrifugation (16 000 rcf, 10
min) and the lysate was incubated on a vertical rotator overnight at +4 °C with 1 µg/ml
goat anti-RET (long isoform) antibodies (Santa Cruz Biotechnology) and 40 µl 1:1
protein G Sepharose (Invitrogen) – modified RIPA buffer mixture. Beads were washed
three times (2 500 rcf, 5 min) with ice-cold TBS containing 1 % Triton X-100. Samples
were boiled for 10 min in 100 µl/sample 2x Laemmli buffer and stored in -20 C.
For western blot, samples were boiled and centrifuged as described in chapter 3.3.1
before resolving proteins using 7,5 % SDS-PAGE. After blotting and blocking (also
described in chapter 3.3.1), membranes were incubated overnight at +4 °C or 2 h at RT
with mouse antibodies against phosphotyrosine (Millipore) diluted 1:1000 in TBST
containing 3 % milk, washed and incubated for 45 min at RT with HRP-conjugated anti-
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mouse antibodies (Dako). Membranes were washed, proteins visualized and mem-
membranes then stripped, washed and blocked as described in chapter 3.3.1.
RET was stained as a loading control. Membranes were incubated overnight at +4 °C
or 2 h at RT with goat anti-RET (long isoform) antibodies (Santa Cruz Biotechnology)
diluted 1:500 in TBST containing 3 % milk, washed and incubated for 45 min with anti-
goat antibodies (Daco) diluted 1:1000 in TBST containing 3 % milk. Membranes were
washed and proteins visualized as described in chapter 3.3.1.
3.4 Survival assay
Preparation of plates, isolation and plating of midbrain neurons was performed by
Zheng Congjun in accordance with a method developed by Dr. Andressoo [30]. 3 mm2
microislands on 4-well plates (Nunc) were coated with 1 mg/ml poly-L-ornithine (Sigma)
in 0,15 M borate buffer (pH 8,7), washed with PBS and air-dried.
3.4.1 Isolation and plating of midbrain cells
Approximately 1 mm2 of the midbrain floor was extracted from E13.5 NMRI mice in
Dulbecco’s PBS at RT and washed 3 times with Ca2+/Mg2+-free Hank’s Balanced Salt
Solution (HBSS). The tissue was incubated with 0,5 % trypsin in Ca2+/Mg2+-free HBSS
for 20 min at 37 °C before adding 50 % FBS and 2 mg/ml DNAse (Roche). Cells were
dissociated by pipetting, washed twice (1200 rcf, 5 min) with culture medium
(Neurobasal Medium, Invitrogen, supplemented with B-27, Invitrogen, 2 mM L-
glutamine and 100 µg/ml Primocin, InvivoGen). 24 000 cells were plated per
microisland in 4 µl of culture medium. Cells were allowed to attach for 1-2 h before the
addition on 500 µl of culture medium containing 0,1 % DMSO (negative control) and
compounds (0,003-2 µM) or GDNF (30 ng/ml, positive control).
3.4.2 Tyrosine hydroxylase staining
Dopaminergic neurons were visualized using antibodies against tyrosine hydroxylase
(TH) on 5th day in vitro. Cells were fixed with 4 % paraformaldehyde (PFA) in PBS for
15 min at RT, washed three times with PBS and permeabilized with TBSTX (50 mM
Tris-HCl, pH 7,4, 150 mM NaCl, 0,4 % Triton X-100) three times for 15 min. After
blocking for 1 h at RT with TBSTX containing 10 % horse serum, cells were incubated
overnight with sheep antibodies against tyrosine hydroxylase (Chemicon) diluted 1:500
in TBSTX containing 1 % horse serum. Cells were washed three times with TBSTX and
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incubated for 1 h at RT with Cy3-conjugated antibodies against sheep immunoglobulins
(Jackson Immunoresearch) diluted 1:500 in TBSTX containing 1 % horse serum. Cells
were washed with TBSTX for 15 min three times, once with PBS and once with H2O
before mounting in Gelvatol mounting medium.
3.4.3 Quantification of TH-positive cells
Microislands (Figure 6) were photographed with the Lumar V12 fluorescence
stereomicroscope using a Cy3 filter (Zeiss) . Non-specific staining on the edges of the
microislands and major distortions such as those caused by air bubbles were manually
deleted using ImageJ software (version 1.43u).
Figure 6. A microisland under fluerescent light showing TH-positive cells.
TH-positive cells were counted using Image-Pro Plus (version 5.1.2.59, Media
Cybernetics) in a blinded manner so that the quantification data were matched with
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sample information only after completion of the counting. Counting was based on pixel
intensity and size which were manually adjusted to create objects matching cell bodies
(Figure 7).
Figure 7. Computer-aided count of TH-positive cells after manual adjustments.
Effect on survival was determined using paired Student’s t-test (p < 0,05). Results from
three individual experiments with a minimum of four repeats per treatment group were
used.
4 Results and discussion
The purpose of this graduate study was to characterize four synthetic molecules
potentially  functionally  similar  to  GDNF.   These  compounds  (BT13,  BT16,  BT17  and
BT18) were developed the research group led by Academy Professor Mart Saarma
using reporter cell lines (Strat?LUC, NOstrat?) described in detail  in chapter 3.2. The
first phase in this study was to confirm that the compounds do indeed induce the same
cellular response in the reporter cells as GDNF does and do so dose-dependently. To
do this, cells expressing the complete GDNF receptor complex i.e. RET and GFR?1 (the
Strat?LUC cell line) together with the luciferase reporter gene-based MAPK pathway
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monitoring system were used to study compounds’ ability to promote MAPK activation.
In addition, cells expressing the reporter gene system and RET only (NOstrat??cell line)
were used to investigate whether or not compound-induced activation requires the
presence of GFR?1.
4.1 Luciferase assay
All four compounds activated luciferase expression dose-dependently both in
Strat?LUC and in NOstrat? cells (Figure 8). This suggests that GFR?1 is not
necessary for compound-induced activation of luciferase expression. However, the
presence of GFR?1 appears to increase the response significantly.
Figure 8.  Luciferase assay shows dose-dependent activation of luciferase expression by
compounds BT13 (A),  BT16 (B),  BT17 (C)  and BT18 (D) both in  Strat?LUC (RET +
GFR?1) and NOstrat? (RET only) cells. Strat?LUC cells responded to GDNF (positive
control, 25 ng/ml panels A and B, 50 ng/ml panels C and D) whereas Nostrat? cells
did  not  (as  determined  using  t-test,  p  <  0,05).  CTR  –  untreated  cells,  LCPS  –
luminescence counts per second.
When compounds BT13 and BT16 were tested the GDNF concentration of 25 ng/ml
stimulated luciferase activity approximately twice as much compared to untreated cells
(Figure 8, panels A and B) whereas with BT17 and BT18 the GDNF-induced signal was
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20 times higher than that of the untreated cells (Figure 8, panels C and D). This dis-
discrepancy might be explained by a pipetting error, lower concentration (25 ng/ml
instead of 50 ng/ml), loss of biological activity or the combination of these three factors.
GDNF did however serve its purpose as a positive control as the response in both
experiments was statistically significant compared to untreated cells (t-test, p < 0,05).
As expected, GDNF was unable to produce significant activation of luciferase
expression without its co-receptor.
Luciferase assay proved to be an excellent tool for screening purposes. It is not only
sensitive and fast but also cost and labor efficient. However, the evidence it provides is
indirect and the observed activation of luciferase expression by compounds might be
contributed to factors unrelated to the ones mediating the GDNF-induced response.
Thus, direct phosphorylation assays were employed to investigate the compounds’
ability to activate RET and its downstream targets AKT and ERK1/2.
4.1 Phosphorylation assay: ERK1/2 and AKT
Ability of the compounds to activate intracellular signaling cascades MAPK and PI3K
was studied by direct phosphorylation assay of their components ERK1/2 and AKT,
respectively, using GFR?1-transfected MG87RET cells (see chapter 3.1.) and western
blot. Activation was determined by comparing the degree of phosphorylation of these
proteins in cells treated with compounds (1-50 µM) or GDNF (50-100 ng/ml, positive
control) to phosphorylation in untreated cells (negative control). GAPDH was stained as
a loading control.
To estimate the optimal stimulation time for dose-dependence assays, cells were
exposed to compounds for 1, 5, 15, 45 and 90 minutes (Figure 9) unless otherwise
stated - failure to adhere to these time-points occurred in experiments regarding
compounds BT13 (Figure 9, panel A) and BT18 (Figure 9, panel D). Cells were also
treated with GDNF using same time-points in order to compare time-dependent
activation induced by GDNF and by compounds.
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Figure 9.  Compounds BT13 (A), BT16 (B), BT17 (C) and BT18 (D, E) activate AKT and ERK1/2
time-dependently. Western blotting (WB) of GFR?1-transfected MG87RET fibroblasts
stimulated with compounds (50 µM) or GDNF (50 ng/ml, positive control) for 1 – 90
min (unless otherwise stated). CTR – untreated cells, MW – molecular weight.
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Compounds BT13 (Figure 9, panel A), BT16 (Figure 9, panel B) and BT17 (Figure 9,
panel C) activated ERK1 (upper band) and ERK2 (lower band). BT18 did so initially
(Figure 9, panel D), but when the experiment was repeated due to a missing time-point,
the compound produced no observable ERK1/2 activation (Figure 9, panel E). The
same occurred with GDNF (positive control) in this experiment, which contradicts
results from a multitude of published studies and as well as data acquired in this study.
One possible reason for this inconsistency is the transfection procedure which was
different from the procedure used in all other experiments. In this experiment, the
transfection reagent was incubated overnight with the cells instead of 4-6 hours as
recommended by the manufacturer. This might have influenced the outcome as
Lipofectamine 2000 has been reported to activate ERK1/2 [Runeberg-Roos, P.,
unpublished observations]. High baseline activity could very well mask any effect
produced by compounds and GDNF. The other possible explanation is the quality of
antibodies that were from a different batch. It was suspected that these antibodies
recognize total ERK1/2 instead of phosphorylated forms of these proteins. The intensity
of stained pERK1/2 (or total ERK1/2, if antibodies were flawed) was indeed elevated in
all cells in the experiment and demanded unusually low exposure time for detection.
Most of the data indicate that activation of ERK1/2 by GDNF peaks between 1 and 5
minutes. This is most evident in panel B (Figure 9) where ERK1/2 activation clearly
decreases after the 5 minute peak. Panel A (Figure 9) shows the same decrease
although not as clearly due to unequal loading. In panel D (Figure 9) the 5 minute time-
point is missing but the decrease after 15 minutes is consistent with conclusions based
on images shown in panels A and B. Surprisingly data in panel C (Figure 9) indicates
that levels of pERK1/2 continue to stay elevated even after 45 minutes. ERK1/2
activation induced by BT13, BT16 and BT17 (panels A, B and C in Figure 9) also
peaked between 1 and 5 minutes indicating that they activate ERK1/2 with similar time-
dependence to GDNF. Whether or not BT18 (panels D and E in Figure 9) does so
cannot be concluded due to the missing 5 minute time point and aforementioned
problems with the transfection.
All four compounds (BT13, BT16, BT17 and BT18, Figure 9, panels A to E) activated
AKT. Activation induced by BT13, BT16 and BT17 apparently keeps increasing with
time and was at its highest after 90 minutes (panels A to C, Figure 9). Compound BT18
behaved differently with activation reaching its peak after 15 minutes after which the
signal began to drop (panels D and E, Figure 9). GDNF-induced AKT activation
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appears to reach its peak between 5 and 45 minutes as data indicate in panels A and E
or between 15 and 45 minutes as suggested by data shown in panels B and C (Figure
9). Notably, AKT activation by GDNF decreases between 45 and 90 minutes whereas
with compounds BT13, BT16 and BT17 the activation increases (panels A, B and C in
Figure 9). Time-dependence in AKT activation by compound BT18 (panel E, Figure 9)
appears similar to that induced by GDNF.
Combined data from luciferase and phosphorylation assays were considered enough to
conclude MAPK activation by all four compounds (BT13, BT16, BT17 and BT18).
Therefore, focus was given to dose-dependence in compound-induced AKT activation.
Stimulation time of 90 minutes was selected based on the results from time-
dependence assays.
All four compounds (BT13, BT16, BT17 and BT18) activated AKT in a dose-dependent
manner (Figure 10) although the loading is questionable due to problems with GAPDH
detection. Fading of chemiluminescence during visualization was unexceptionally rapid.
Interpretation becomes problematic if the substrate is exhausted during visualization.
However, the chance of unequal loading producing such a consistent pattern of dose-
dependency seems unlikely.
Figure 10. AKT is activated dose-dependently by compounds BT13, BT16, BT17 and BT18.
Western blotting (WB) of GFR?1-transfected MG87RET cells stimulated with varying
concentrations of compounds  (1-50 µM) or GDNF (50 ng/ml, positive control) for 90
min. CTR – untreated cells, MW – molecular weight.
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Compound BT16 exhibits signs of toxicity. Data presented in Figure 10 (upper panel)
indicates that the concentration of 50 µM was less efficient in activating AKT than that
of 20 µM. The higher concentration might have caused cell damage rendering the cells
unable to respond to stimuli normally.
It was concluded that all four compounds activate not only MAPK but also AKT
indicating they promote the activation of the antiapoptotic PI3K pathway. It was of
interest to determine whether or not the compounds do so by activating RET and if so,
is GFR?1 required.
4.2 Phosphorylation assay: RET
The involvement of RET in compound-induced activation of MAPK and PI3K pathways
was studied using MG87RET cells transfected with GFP or GFR?1. RET was
immunoprecipitated and analyzed using western blot. Degree of RET phosphorylation
in cells treated with compounds (5-50 µM) or GDNF (75-100 ng/ml, positive control)
was compared to that in untreated cells (negative control). RET was stained as a
loading control. Comparisons were also made between cells transfected with GFR?1
and cells transfected with GFP to study the compounds’ ability to signal through RET
without GFR?1. RET phosphorylation assays were limited to compounds BT13 and
BT18 due to unavailability of BT16 and BT17. Moreover, some of the data points are
inconclusive owing to unequal loading that could not be adjusted despite of numerous
attempts.
Compound BT13 induced RET phosphorylation in GFR?1-transfected MG87RET cells
(Figure 11, panel A). At least 10 and 25 µM concentrations of BT13 produced a notable
phosphorylation compared to untreated cells. Whether or not concentrations of 5 and
50 µM also activated RET cannot be concluded because of the differences in amount
of loaded protein. Because of this issue the BT13-induced RET phosphorylation in
GFP-transfected cells is even less clear. Yet at least concentration of 50 µM seems to
induce phosphorylation compared to GDNF that is not able to function without GFR?1
and can be regarded as a negative control.
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Figure 11. Compound BT13 induces RET phosphorylation. Western blot of GFP/GFR?1-
transfected MG87RET fibroblasts treated for 15 min with varying concentrations of
BT13  or  GDNF  (positive  control,  75  ng/ml,  panel  A,  100  ng/ml,  panel  B.  CTR  –
untreated  cells.  MW  –  molecular  weight.  IP  –  immunoprecipitation.  pY  –
phosphotyrosine. WB – western blot.
Compound BT18 appears to phosphorylate RET in concentration of 50 µM both in
GFP-transfected (compared to GDNF) and in GFR?1-transfected cells (Figure 11,
panel B). No solid conclusion can be made from data points corresponding to other
concentrations.
To conclude, results from RET phosphorylation assay indicate compounds BT13 and
BT18 activate RET. This and data from ERK1/2 and AKT phosphorylation assays
suggests functional similarity between BT13, BT18 and GDNF. However, in
accordance to data from luciferase assays, compounds seem to be able to activate
RET independent of GFR?1. It was concluded that the combined results from
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phosphorylation assays warrant assaying compounds’ effect on survival of DA neu-
neurons.
4.3 Survival assay
Ability of compounds to promote survival of dopaminergic neurons was studied using
primary murine (NMRI) embryonic (E13,5) midbrain neurons. Cells were cultured for 5
days in vitro (5 DIV) after which they were stained using tyrosine hydroxylase staining
and counted in a blinded manner. Number of TH-postive cells after 5 DIV treated with
compounds (0,003 µM – 5 µM) or GDNF (30 ng/ml, positive control) was compared to
the number TH-positive cells in the untreated groups (negative control). Comparisons
were made between three independent experiments with at least four repeats per
treatment group using two-tailed, paired Student’s t-test to determine statistically
significant difference between the groups (p < 0,05). Due to limitations on time and
material only results for six concentrations of BT13 and three concentrations of BT18
were acquired (Figure 12). For other concentrations and compounds BT16 and BT17,
there was not enough statistical power to determine effect on survival (data not shown).
Figure 12.BT13 significantly promotes survival of dopaminergic embryonic neurons in 1 µM (p
<0,05) whereas no significant survival promoting effect was observed with BT18 on
any of the tested concentrations. Concentration of GDNF was 30 ng/ml. CTR –
untreated cells.
Compound BT13 significantly promotes the survival of primary embryonic
dopaminergic neurons in 1 µM concentration (Figure 12, left panel). No such effect
could be determined for the other concentrations used. Moreover, no survival
promoting effect by BT18 in tested concentrations could be shown (Figure 12, right
panel). However, BT18 concentration of 0,03 µM came very close (p = 0,0504). Further
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experimenting is necessary to establish possible survival promoting effects of com-
compounds BT16, BT17 and BT18.
5 Conclusions and perspectives
The purpose of the work presented was to show functional similarities between GDNF
and four synthetic, potential small-molecule GDNF mimics (BT13, BT16, BT17 and
BT18). Methods and the order in which the methods were employed were chosen with
time and cost efficiency in mind. First, the compounds were tested using the luciferase
assay designed to show activation of the MAPK pathway that is known to mediate
GDNF’s neurotrophic effects. Treatment with all four compounds led to an increase in
luciferase expression suggesting compound-induced MAPK activation. This called for
further experiments that constitute the second and third phase of this study. During
the second phase, phosphorylation immunoassays were used to investigate whether
compounds activate not only MAPK but also another important pathway, the PI3K
cascade. As compound-induced activation of both signaling pathways was shown, it
was important to determine the involvement of RET and GFR?1, the components of
the GDNF receptor complex. This constitutes the third phase of this study. Because the
compounds  BT16  and  BT17  were  not  available,  RET  phosphorylation  assays  were
limited to BT13 and BT18 which did fortunately display some, yet not conclusive,
activation of RET (also without GFR?1, however, supporting GFR?1-independent
activation seen in luciferase assay). Data compiled from the luciferase and
phosphorylation assays suggesting warranted for the final and perhaps the most
important part of this study, which focused on investigating the possible survival
promoting effects of the compounds BT13 and BT18 (as BT16 and BT17 were not
available). Exposure to compound BT13 was found to significantly increase survival of
primary DA neurons in vitro. BT18 did not show such an effect based on data that was
acquired. To conclude, the aims set for this study were mostly met.
Results indicate that the compound BT13 and GDNF share functional similarities, most
importantly the survival promoting effect on cultured dopaminergic neurons. The
reason behind pursuing the development of small-molecule alternatives to GDNF is to
ultimately be able to treat Parkinson’s disease. Results from this study are certainly
promising but an aeon away from any such clinical applications. Further studies are
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required to address a multitude of issues including efficacy in vivo and numerous pos-
possible unwanted effects on cell populations throughout the body expressing RET or
RET and GFR?1.
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